CD5/CD7 CAR-T
Phase 2Cell therapy
CD5/CD7 CAR-T is one of 28 biologic programs targeting T-cell acute lymphoblastic leukemia. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
28 competitors in T-Cell Acute Lymphoblastic Leukemia
#DrugCompanyPhaseTrials
1Cytosar
TevaPhase 3
Arranon
NovartisPhase 3
Trexall
Jazz PharmaceuticalsPhase 3
Oncovin
Eli LillyPhase 3
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Rayos
RRoxane Laboratories
Phase 3
Purinethol
SStason
Phase 3
Venclexta
AbbViePhase 2
Darzalex
Johnson & JohnsonPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CD5/CD7 CAR-T. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 2[1]
- Company
- EEssen Biotech